932841-41-3 Usage
Acid derivative of chloroquinoline
The compound is derived from chloroquinoline, a class of chemicals often used in the pharmaceutical industry, indicating a potential connection to pharmaceutical applications.
Quinoline ring
The presence of a quinoline ring, a heterocyclic aromatic compound, contributes to the chemical structure and may influence its potential applications.
Chlorine atom at the 6th position
The addition of a chlorine atom at the 6th position on the quinoline ring may affect the compound's reactivity, stability, and potential pharmaceutical applications.
Carboxylic acid group
The presence of a carboxylic acid group (-COOH) suggests that the compound has acidic properties and may participate in reactions involving acids or bases.
Butoxyphenyl group attached at the 4th position
The attachment of a butoxyphenyl group (a phenyl group connected to a butoxy side chain) at the 4th position may influence the compound's solubility, stability, and interactions with other molecules.
Potential applications in drug development
The compound may have potential applications in the development of new pharmaceuticals for treating various diseases and conditions, although further research and testing are required.
Need for further research and testing
The specific properties and potential uses of 2-(4-Butoxyphenyl)-6-chloroquinoline-4-carboxylic acid would need to be investigated and confirmed through laboratory experiments and studies.
Check Digit Verification of cas no
The CAS Registry Mumber 932841-41-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,2,8,4 and 1 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 932841-41:
(8*9)+(7*3)+(6*2)+(5*8)+(4*4)+(3*1)+(2*4)+(1*1)=173
173 % 10 = 3
So 932841-41-3 is a valid CAS Registry Number.
932841-41-3Relevant academic research and scientific papers
SAR-based optimization of a 4-quinoline carboxylic acid analogue with potent antiviral activity
Das, Priyabrata,Deng, Xiaoyi,Zhang, Liang,Roth, Michael G.,Fontoura, Beatriz M.A.,Phillips, Margaret A.,De Brabander, Jef K.
supporting information, p. 517 - 521 (2013/07/26)
It is established that drugs targeting viral proteins are at risk of generating resistant strains. However, drugs targeting host factors can potentially avoid this problem. Herein, we report structure-activity relationship studies leading to the discovery
